Anpac Bio

Founded in 2010 by interdisciplinary scientists and experts in the fields of medicine, physics, biology, biochemistry, nano-technology, etc., Anpac Bio is considered as one of the pioneers and leaders of multi(pan)-cancer detection, as well as an early inventor and developer in multi-level and multi-parameter cancer screening technology.

Over the past decade, Anpac Bio has focused on break-through innovations, with a multi-disciplinary approach combining nano-technology, biophysical and biomedical technologies, and has overcome the technical challenges of early cancer screening.

Anpac Bio has been carrying out multi-cancer detection tests using its novel and patented cancer differentiation analysis technology (CDA) for cancer risks in general population.  It has accumulated over 300,000 multi-cancer test samples and data.  It is saving lives.

CDA Early Cancer Risk Assessment

CDA and Gene combination test

APCS Pan-Cancer Screening

CDA and Gene combination test

ADME Third Immune Defense Test

CDA and Gene combination test

Hot News

Hot Video


Shanghai Changzheng Hospital
Fudan University Science Life Of School
Changhai Hospital
Shanghai Tumor Hospital
Shanghai Jiaotong University School Of Medicine